REBECCA M PARKER

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner VA BEACH, VA NPI 1639610512

General Payments — all program years on this page

$1,746.12

  • Category: General Payments
  • Program years: PY2021–2024
  • Record count: 103
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $399.80 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $399.8020

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Novo Nordisk AS $149.958
ABBVIE INC. $130.405
GlaxoSmithKline, LLC. $38.212
Amgen Inc. $31.632
Astellas Pharma US Inc $31.192
OptiNose US, Inc. $18.421

By program year

Program yearAmountRecords
2021 $509.2230
2022 $394.1926
2023 $442.9127
2024 $399.8020

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1100270699 Novo Nordisk Inc $21.77 06/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100304691 Novo Nordisk Inc $18.26 05/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100309073 Novo Nordisk Inc $18.31 03/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100357082 Novo Nordisk Inc $20.33 09/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100507913 Novo Nordisk Inc $17.53 10/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100533891 Novo Nordisk Inc $20.17 02/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100551793 Novo Nordisk Inc $11.41 07/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100582186 Novo Nordisk Inc $22.17 04/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107791241 ABBVIE INC. $32.02 01/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107791246 ABBVIE INC. $14.88 01/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107791251 ABBVIE INC. $21.15 04/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107791255 ABBVIE INC. $32.73 05/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107791260 ABBVIE INC. $29.62 08/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116112696 GlaxoSmithKline, LLC. $15.04 11/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116427296 GlaxoSmithKline, LLC. $23.17 06/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117347112 Amgen Inc. $18.46 06/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117649164 Amgen Inc. $13.17 11/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139491486 Astellas Pharma US Inc $14.35 02/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139534258 Astellas Pharma US Inc $16.84 08/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142192153 Optinose US, Inc. $18.42 06/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.